143
FDA Approves <a href="https://www.archynetys.com/top-10-breast-oncology-advancements-in-2024/" title="Top 10 Breast Oncology Advancements in 2024">Pembrolizumab</a> Regimen for Head and Neck Cancer
“`html
FDA Approves Pembrolizumab Regimen for Head and Neck Cancer
The FDA has approved a new treatment option using pembrolizumab for resectable locally-advanced head and neck squamous cell carcinoma.
The Food and Drug Administration (FDA) has given the green light to a treatment plan involving pembrolizumab,administered both before and after surgery,to enhance results for individuals with resectable locally-advanced head and neck squamous cell carcinoma (HNSCC).
This approval specifically targets HNSCC tumors exhibiting PD-L1. The regimen includes pembrolizumab as a single agent in the neoadjuvant phase,followed by radiation with or without cisplatin post-surgery, and continued pembrolizumab as a single agent for maintenance.
